Patheon IncTSX: PTI

Patheon Updates Outlook for Q1 2006

· Issued by Patheon Inc via CNW
Website: www.patheon.com

TORONTO, Feb. 16 /CNW/ - Patheon Inc. (TSX: PTI) today announced that
based on a preliminary review of 2006 results for the first quarter ended
January 31, 2006, it expects that the previously disclosed difficulties with
Omnicef(R) production at its Carolina, Puerto Rico facility will impact
earnings by approximately 6 cents per share in the first quarter, not 3 cents
per share as anticipated when the Company reported 2005 year end results in
December 2005.
The Company also reports that, in addition to the effect of normal
seasonality and holiday production shutdowns in the first quarter, net
earnings will be further reduced by other developments, including delays in
production volumes at certain sites in both Europe and North America, and
lower revenues from pharmaceutical development services projects, primarily in
North America, caused, in part, by capacity constraints. The Company expects
to report a loss of approximately 7 cents per share in the first quarter,
before one-time charges relating to the refinancing completed in December
2005.
At Carolina, initiatives to improve production line speeds are resulting
in improved yields, and a third production line was validated earlier this
month. These two initiatives are expected to result in higher production
levels for the balance of the year. The delays and production constraints
experienced at certain other of Patheon's manufacturing sites are expected to
be resolved over the next three quarters of the year.
Management, however, cautions that net earnings for the full year, before
one-time items, may be lower than those of a year ago.
Patheon will report detailed 2006 first quarter results on Friday,
March 3, 2006 at approximately 7:00 a.m. (Eastern Standard Time). A webcast
conference call with financial analysts will be held on Friday, March 3, 2006
at 10:00 a.m. (Eastern Standard Time). Interested parties are invited to
access the live call, via telephone, in listen-only mode, at (416) 644-3426
(Toronto and International) or toll free at (800) 814-4862 (U.S., including
Puerto Rico). Listeners are encouraged to dial in five to 15 minutes in
advance to avoid delays. A live audio webcast, with a slide presentation, will
also be available via the web at www.patheon.com.
A telephone replay of the conference call will be available between
March 3, 2006 and March 17, 2006 by calling (416) 640-1917 or (877) 289-8525
(toll free) and entering identification number 21175495, followed by the "No."
key. The webcast will also be archived on www.patheon.com for three months.

About Patheon

Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug
development and manufacturing services to the international pharmaceutical
industry. Patheon operates a network of 14 facilities in the United States,
Canada and Europe, employing more than 5,900 people and serving a client base
of 200 pharmaceutical and biotechnology companies.

Forward-Looking Statement

This news release contains forward-looking statements with respect to
Patheon, including its business operations and strategy and financial
performance and condition. Although management believes that the expectations
reflected in such forward-looking statements are reasonable, such statements
involve risks and uncertainties. Actual results may differ materially from
those expressed or implied by such forward-looking statements. Factors that
could cause actual results to differ materially from expectations include, but
are not limited to, currency fluctuations, the level of outsourcing services
required by the pharmaceutical companies (and in particular our clients), the
impact of changes in pharmaceutical development and manufacturing regulations
and general economic and market factors (including inflation and changes in
laws) and other factors discussed in materials filed with applicable
securities regulatory authorities from time to time.
%SEDAR: 00001700E

Patheon Inc on 6ix

Earlier from Patheon

Later from Patheon

All Patheon news releases